High ORR with trastuzumab-pkrb plus GemCis in our study was in line with the results of earlier small-sized studies showing tumour response to HER2-targeted agents in the majority of included BTC patients [25,26,27,29,30]. The gene discussed is ERBB2; the disease is neoplasm.